Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD38-SADA + Lutetium Lu 177-DOTA |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD38-SADA | Anti-CD38 scFv/Anti-DOTA scFv Fusion Protein CD38-SADA | CD38 Antibody 20 | CD38-SADA is a fusion protein comprising a single chain variable fragment targeting CD38, a single chain variable fragment targeting the chelating agent DOTA, and a self-assembling and disassembling (SADA) domain, which potentially allows selective delivery of a radioactive payload to CD38-expressing tumor cells (NCI Drug Dictionary). | |
Lutetium Lu 177-DOTA | 177Lu-DOTA|Lu-177-DOTA | Lutetium Lu 177-DOTA is a radioconjugate comprising the radionuclide Lutetium-177 linked to the chelating agent DOTA, which potentially delivers beta radiation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05994157 | Phase I | CD38-SADA + Lutetium Lu 177-DOTA | Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |